Platelet adhesion onto immobilized fibrinogen under arterial and venous in-vitro flow conditions does not significantly differ between men and women

BackgroundGender-related differences in incidence of arterial thrombosis have been a focus of interest for years. The platelet integrin αIIbβ3 is primarily responsible for the interaction between platelets and fibrinogen and consecutive thrombus growth. In this study, we evaluated platelet adhesion onto immobilized fibrinogen under venous and arterial flow conditions in men and women.MethodsPlatelets in whole anticoagulated blood were labelled with the fluorescence dye Mepacrine and perfused through the rectangular flow chamber over glass cover slips coated with fibrinogen (shear rates of 50 s-1, 500 s-1 and 1500 s-1). A fluorescence laser-scan microscope was used for visualisation and quantification of platelet adhesion at 15 seconds, 1 and 5 minutes after the start of perfusion.ResultsDuring perfusion, the platelet adhesion linearly increased in regard to exposition time and shear rate. After five minutes of perfusion the platelet adhesion onto immobilized fibrinogen showed no significant gender related difference, neither at 50 s-1 nor at 500 s-1 and 1500 s-1 (p > 0.05), respectively. No significant difference in platelet adhesion onto immobilized fibrinogen, in regard to the menopausal status, was either observed (p > 0.05).ConclusionIn our in vitro experimental system, hormonal differences between men and women did not influence platelet adhesion onto immobilized fibrinogen, neither under venous nor under arterial rheological conditions.

[1]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[2]  P. Bray,et al.  Genetics of Arterial Prothrombotic Risk States , 2001, Experimental biology and medicine.

[3]  Marilyn E. Miller,et al.  Influence of hormones on platelet intracellular calcium. , 1995, Thrombosis research.

[4]  W. März,et al.  Rapid genotyping of human platelet antigen 1 (HPA-1) with fluorophore-labelled hybridization probes on the LightCycler. , 1999, British journal of haematology.

[5]  J. Bar,et al.  The Effect of Estrogen Replacement Therapy on Platelet Aggregation and Adenosine Triphosphate Release in Postmenopausal Women , 1993, Obstetrics and gynecology.

[6]  V. Fuster,et al.  Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. , 2004, European heart journal.

[7]  D. Herrington,et al.  The Heart and Estrogen/Progestin Replacement Study , 1999, Drugs & aging.

[8]  Marilyn E. Miller,et al.  Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. , 1994, Thrombosis research.

[9]  M. Mascelli,et al.  Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications , 2009, Pathology & Oncology Research.

[10]  S. Shattil Function and Regulation of the β3 Integrins in Hemostasis and Vascular Biology , 1995, Thrombosis and Haemostasis.

[11]  H. C. van der Mei,et al.  Development and use of a parallel-plate flow chamber for studying cellular adhesion to solid surfaces. , 1992, Journal of biomedical materials research.

[12]  Zaverio M. Ruggeri,et al.  Platelets in atherothrombosis , 2002, Nature Medicine.

[13]  J. Lawson,et al.  Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase—deficient mice , 2005, Nature Medicine.

[14]  C. Kooperberg,et al.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. , 2003, JAMA.

[15]  Valentin Fuster,et al.  Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences , 2001, Annals of Internal Medicine.

[16]  P. Bray,et al.  The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. , 2001, Archives of pathology & laboratory medicine.

[17]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[18]  Brian Savage,et al.  Initiation of Platelet Adhesion by Arrest onto Fibrinogen or Translocation on von Willebrand Factor , 1996, Cell.

[19]  R H Myers,et al.  Genetic and Environmental Contributions to Platelet Aggregation: The Framingham Heart Study , 2001, Circulation.

[20]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[21]  W. März,et al.  Rapid genotyping of human platelet antigen 1 (HPA‐1) with fluorophore‐labelled hybridization probes on the LightCyclerTM , 1999 .

[22]  B. Kudryk,et al.  Fibrinogen in Human Atherosclerosis , 1994, Annals of the New York Academy of Sciences.

[23]  S. Suciu,et al.  Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. , 1986, The Journal of urology.

[24]  L. McIntire,et al.  Adhesion of platelets to surface-bound fibrinogen under flow. , 1996, Blood.

[25]  S. Alper,et al.  Hemodynamic shear stress and its role in atherosclerosis. , 1999, JAMA.